¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷ : 2023-04-07

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷ : 2023-04-07
±³À°ÀÏÀÚ : 2023-04-07
±³À°Àå¼Ò : ¾Ú¹ö¼­´õ ¼­¿ï Ç®¸¸È£ÅÚ¿¡¼­

±³À°ÁÖÁ¦ : 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¿ìº´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ

¼¼ºÎ¼ö°­·á : 80,000¿ø  

ºñ°í Àü°øÀÇ, °£È£»ç, ±âŸ 50000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 08:20~08:40 Real-world experience of emicizumab prophylaxis in young children with hemophilia in China: retrospective data from China Wanru Yao(Beijing Children)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 08:40~09:00 TSUBASA: A prospective study evaluating the association between physical activity and bleeding events in patients with hemophilia A without FVIII inhibitors during emicizumab prophylaxis Keiji Nogami(Nara Medical University, Japan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 09:00~09:20 Gene therapy for hemophilia in China Feng Xue(Institute of Haematology and Blood Diseases Hospital, China)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 09:20~09:40 Hemophilia A murine models with transduced human factor IX and X for applications of factor VIII mimicking bi-specific antibodies Sheng Chieh Chou(National Taiwan University Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:05~10:25 Prothrombotic effect of emicizumab in an in vitro perfusion flow-chamber experiment using whole blood patients with von Willebrand disease Kenichi Ogiwara(Nara Medical University, Japan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:25~10:45 Managements of hemoperitoneum associated with ovulation in type 2 von Willebrand Disease: a single-institute experience in Taiwan Hsuan-Yu Lin(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:45~11:05 Chinese guidelines on the diagnosis and management of von Willebrand disease Ziqiang YuJie Yin(The First Affiliated Hospital of Soochow University, China)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 11:05~11:25 Genetic confirmation of Glanzmann thrombasthenia and other inherited platelet function disorders in Korea Ye Jee Shim(Keimyung University Dongsan Hospital, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 11:35~12:10 Status of hemophilia A and B gene therapies in 2023 Glenn Pierce(World Federation of Hemophilia, Canada)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 12:10~12:50 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MG1113 in Healthy Subjects and Hemophilia Patients Jung Woo Han(Yonsei University Health System, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 13:00~13:40 Non-inversion variant in sporadic hemophilia A originate mainly in female: a result of variant-origin and timing study Ming-Ching Shen(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 13:50~14:10 Therapeutic Outcomes of EHL Compared with SHL Clotting Factors in Patients with Severe Hemophilia in Taiwan Shyh-Shin Chiou(Kaohsiung Medical University Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:10~14:30 Joint monitoring using musculoskeletal ultrasound in Japan Azusa Nagao(Ogikubo Hospital, Japan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:30~14:50 Novel classification system of hemophilic pseudotumor for surgical treatment Xisheng Weng(Peking Union Medical College Hospital, China)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:50~15:10 Perioperative replacement of factor concentrates for orthopedic surgery in hemophilia A patients with hemophilic arthropathy Jae Joon Han(Kyung Hee University, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:35~15:45 A Phase 3 Study to Evaluate Efficacy and Safety of Fitusiran in People with Hemophilia A or B who Switched Factor or Bypassing Agent Prophylaxis Chur-Woo You(Daejeon Eulji Medical Center, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:45~15:55 Patients¡¯ and parents¡¯ satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study Ji Yoon Kim(Kyungpook National University School of Medicine)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:55~16:05 Analysis of Antithrombin Levels and Thrombin Generation a Phase 3 Study of Fitusiran in People with Hemophilia A or B Without inhibitors Alok Srivastava(Christian Medical College, India)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 16:05~16:15 The Comparisons of Deep Learning Algorithms to Grade Hemophilic Arthropathy on X ray films Shao Li Han(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 16:15~16:25 Plasma long non-coding RNAs lncDC and THRIL as diagnostic markers of adult primary ITP Xin Li -> Nan Jiang(Qilu Hospital, China)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷ : 2023-04-07""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â ´ëÇѽºÆ÷Ã÷°úÇС¤¿îµ¿ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-08
´ÙÀ½±Û ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦2ȸ ¾ÆÅäÇÇÇǺο° Ä¡·á ½ÉÆ÷Áö¿ò : 2023-04-07
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20775 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 1±â(1ÀÏÂ÷) : 2024-06-13 0 2 2024-05-27
20774 ºÎ»ê (¿Â¶óÀÎ) ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ºÎ»ê¡¤¿ï»ê¡¤°æ³² ÁöºÎȸ 2024³â 06¿ù Çмú´ëȸ : 2024-06-13 0 4 2024-05-27
20773 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç(1ÀÏÂ÷) : 2024-06-13 0 2 2024-05-27
20772 ´ë±¸ 2024 Á¦2Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ ´ë±¸°æºÏÁöºÎÇÐȸ : 2024-06-13 0 7 2024-05-27
20771 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-13 0 10 2024-05-27
20770 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-13 0 3 2024-05-27
20769 ¼­¿ï 2024³â ±Ýõ±¸ÀÇ»çȸ 1Â÷ ¿¬¼ö±³À°(¿ì¿ïÁõ ¾àÁ¦, ÇǺÎÁúȯ, CBC¿Í LFT, À§¿°) : 2024-06-12 0 1 2024-05-27
20768 ¼­¿ï 2024 Á¦3ȸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï¡¤Èñ±ÍÁúȯ ±Øº¹»ç¾÷ ¿¬±¸ÀÚ SKILL-UP Workshop : 2024-06-12 0 1 2024-05-27
20767 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦78Â÷ °æ±âÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-11 0 1 2024-05-27
20766 ±¤ÁÖ Á¦180Â÷ ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ±¤ÁÖ¡¤Àü³²Áöȸ ÇмúÁý´ãȸ : 2024-06-11 0 6 2024-05-27
20765 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ºÎ»ê,¿ï»ê,°æ³²Áöȸ - Á¦362Â÷ ¿ù·ÊÇмúȸ : 2024-06-11 0 10 2024-05-27
20764 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-11 0 5 2024-05-27
20763 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(ÀÇ»ç) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-06-11 0 7 2024-05-27
20762 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Á¦ 32ȸ Á¤±â Áý´ãȸ : 2024-06-10 0 9 2024-05-27
20761 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø Á¦16ȸ KOALA Symposium 2024 : 2024-06-09 0 1 2024-05-27
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷